A phase 2 trial of induction <i>nab</i>‐paclitaxel and cetuximab given with cisplatin and 5‐fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck
Douglas R. Adkins(Washington University in St. Louis), Brian Nussenbaum(Washington University in St. Louis), James S. Lewis(Vanderbilt University Medical Center), Kathryn Trinkaus(Washington University in St. Louis), Barry A. Siegel(Washington University in St. Louis), Wade L. Thorstad(Washington University in St. Louis), Tanya M. Wildes(University of Nebraska Medical Center), Hiram A. Gay(Washington University in St. Louis), Farrokh Dehdashti(Washington University in St. Louis), Paul Mehan, Jessica Ley(Washington University in St. Louis)
Cited by 38
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022
|Journal of the National Comprehensive Cancer Network|2022|532